Notes of Lung CNG Wednesday 7th September 2011, 1.30 pm 3.30 pm Cancer Network Meeting Room, Riverside Park Bromborough

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Notes of Lung CNG Wednesday 7th September 2011, 1.30 pm 3.30 pm Cancer Network Meeting Room, Riverside Park Bromborough"

Transcription

1 Notes of Lung CNG Wednesday 7th September 2011, 1.30 pm 3.30 pm Cancer Network Meeting Room, Riverside Park Bromborough Present Julie Hendry Chair / Consultant Respiratory Physician STHK Martin Walshaw Consultant Respiratory Physician LHCH/RLUH Alison Williams Associate Director MCCN Richard Page Consultant Thoracic Surgeon LHCH Joe Maguire Consultant Oncologist CCO Jim Finnerty Consultant Respiratory Physician COCH Anna Murray Cancer Information Analyst MCCN Martin Ledson Consultant Respiratory Physician LHCH In attendance Pauline Webster, Business Support Co-ordinator, MCCN Chris Romaniuk, Consultant Radiologist, CCO Hülya Wieshmann, Consultant Radiologist, Aintree Heino Hugel, Consultant in Palliative Medicine, Aintree Kay Kennedy, Lung CNS, Wirral attending on behalf of Zaroug Wahbi Lynne Newton, MCCRN, on behalf of Pat Gillis Wendy O Connor, Cardiac Physiology Trainer, Cardiac & Stroke Network Karen Graham, Data Improvement Manager, MCCN 1. Welcome & Apologies Julie Hendry welcomed all to the meeting, introductions were made and apologies received from Paul Walker, John Gosney, Steve Owen, John Holemans, Maria Guerin, Chris McManus, John Littler, Jo Bayly and Zaroug Wahbi. 2. Notes of the previous meeting The notes of the last meeting were agreed as an accurate record. 3. Actions from last meeting 3.1 Network Mesothelioma Review, Mesothelioma audit & national patient survey Diagnosed cases continue to be routinely notified to Martin Ledson and are being recorded on a central database each month. It is likely however that 100% of diagnoses are still not being captured. Martin and Anna are planning to do a mesothelioma audit and it would be helpful to get as much data as possible in order to establish a baseline. (The national meso framework recommends that networks undertake regular audit). Figures from the cancer registry show that there were 99 patients recorded in 2009, (a significant improvement on 2007/2008 figures). Mesothelioma data is recorded on LUCADA and this is the first year (2009) that they have received an adequate response from Trusts. The central database is being used as an interim measure to capture data and will be superseded when full implementation of Somerset Cancer Registry (SCR) across the patch is established. Anna discussed issues regarding the case note exercise that was undertaken which indicates patients being clinically diagnosed with mesothelioma but with no histology or ICD10 recorded. In some cases cancer of the pleura is the recorded diagnosis. Therefore if mesothelioma is not recorded it is not viable to audit those patients. It is important that all Trusts utilise SCR as this can inform outcomes on a national level. Karen Graham highlighted some national work with Page 1 of 6 Page 1 of 6

2 Coroners regarding feedback of mesothelioma findings to Trusts Cancer Services department for investigation so it can be captured on SCR. Maria Guerin and Andrea McIver are planning to review the SSMDT proforma and there may be changes at LHCH in terms of the referral contact for notification of diagnoses. The referral process will be as follows: Completed proformas/relevant information/radiology to be sent to LHCH by Lung Cancer Coordinator from the peripheral Trusts before midday Thursday. Outcome to be faxed back to local MDT point of contact likely to be LCN by midday Friday Maria has confirmed that the mesothelioma patient information prescription material is to be finalised at the Mesothelioma Network meeting in November. The National Patient Survey is due to be rolled out at the end of the year/early Maria also states for information that there is a Patient Carer Day being held on 1st October 2011, Novotel London. An opinion was sought from the group regarding the formal staging system for mesothelioma on LUCADA and SCR. The general consensus is that depending on the performance status this would be TNM staging, although the clinical value of staging is debatable. Julie commented that if patients are referred for active treatment by the SSMDT then an attempt should be made to formally stage them, although it isn t clear whether this is compatible with LUCADA. Karen will circulate the staging criteria and further consult the cancer registries advisory group (for SCR) on this matter. Julie will write to Mick Peake outlining concerns for staging and to seek a strategic view regarding the value of doing so. Action: All to contact Andrea McIvor if further clarification is required regarding the referral process. Karen Graham to circulate staging criteria and consult cancer registries advisory group re staging data Julie to write to Mick Peake outlining concerns re staging. Discuss at the next CNG. Martin Ledson to liaise with Radiologists at the SSMDT to get their agreement on what system is used to stage. 3.2 EGFR service Alison commented in John Gosney s absence: Activity update to be deferred to next CNG Turnaround times and cancer waiting time compliance any issues to liaise directly with John. There has been no feedback received or concerns raised since the last meeting. Issue of 62 day breaches due to delayed EGFR analysis oncologist view is that turnaround time is fine when John is around when he is away everything is batched and the turnaround is longer. A new technician has been appointed at the Royal and their role is to ensure the service continues in John s absence. Action: All to liaise / feedback any issues with John Gosney 3.3 CCO treatment data At the last meeting John Littler was asked to share CCO clinical audit & outcomes data by individual consultant. In John s absence, Joe Maguire went through the previously circulated NSCLC data request for the network April 2006 to March Joe informed the group that the figures have been discussed with the CCO Tumour Specific Group (TSG). The group agreed that there is a need to have a narrative to interpret the data particularly for the survival analysis. It was also agreed that 2008/9 data should now be made available in consideration of 1&2 year survival. Alison commented that it is in the CCO contract that they provide outcomes data to the referring Trust but this has not happened and this is Page 2 of 6 Page 2 of 6

3 the only data that they have received from CCO. It is unclear if the TSG or CCO Trust Board routinely reviews survival statistics and outcome data, but this should be routinely provided for discussion at CNG meetings. In terms of whether CCO are referencing LUCADA to cross check the TNM staging, Joe informed the group that the CCO Audit team use their own database and that LUCADA data can be overwritten. Karen confirmed that if CCO upload their data after LHCH it would automatically overwrite this, including clinical & final staging. From 2012 there will be a new minimum dataset mandated for Trusts to submit data to the Registry on a monthly basis. The Registry is currently in the process of putting a super system in place which will pull together all data to show the whole patient pathway for that cancer episode. This will enable to give the patient s full treatment pathway with outcomes by treating and diagnosing Trust within 6 months and this will be in place by September Action: 2008/2009 data to be requested from CCO TSG by Joe Maguire. Further discussions to take place outside of the meeting to determine what information is required in a report from CCO. Joe Maguire to share information he sent to CCO Chief Executive. 3.3 PET-CT issues Julie welcomed Chris Romaniuk and Hulya Weishmann who were invited to discuss operational PET- CT issues. A number of issues were discussed: Variation in staging on PET-CT reports. A recent local audit highlighted variation in practice amongst the PET-CT reporting Radiologists; Chris & Hulya confirmed that they are happy to provide stage whenever possible and this would be communicated to their colleagues. Jim Finnerty referred to the interpretation of CT scans and would like to see clear and precise reports giving the Radiologist s best opinion and conclusion as there is a risk of missing something in a lengthy report especially if the MDT is discussing 30 cases. Chris commented that it would be useful if all Trusts could send the most recent CT report along with the PET-CT request. Martin Ledson referred to the vetting process currently undertaken by the ARSAC licence holders when scans are requested. The group asked whether this could be removed so that local MDTs could directly request scans and reduce the length of time for the scan to be undertaken. This will need to be discussed with AML and Hulya / Chris agreed to raise this with them. There have been instances where MCCN patients are routinely offered a scan at Preston. If the patient refuses Preston then there are issues about whether the clock should be stopped and this needs clarification. In terms of delays for scans following biopsy; if a staging scan is required then should be no delay. Confusion can be caused by the patient telling AML they have had a biopsy, and this has meant that delays have been experienced. Therefore the term staging PET-CT should be used. Martin Ledson commented about the issue of not having the images available at the same time as the report. This was something that AML had committed to delivering but it doesn t routinely happen at the LHCH. Martin will review previous correspondence with AML to confirm their agreement and discuss further with Alison if necessary. Action: Chris / Hulya to further discuss relevant issues with AML Alison to liaise with Martin Stanley for clarification re Alliance contract re Preston Page 3 of 6 Page 3 of 6

4 4. Palliative Care and referral to the cordotomy service presentation Referral pathway for percutaneous cordotomy.ppt At the last meeting Julie referred to the palliative care section of the mesothelioma pathway with regards to pain management / cordotomy. Clinicians can refer patients directly to Consultants in Palliative Care at Aintree as Dr Heino Hugel has a joint clinic with the pain team at the Walton Centre. Patients are assessed pre and post procedure by the multi-disciplinary team. Dr Heino Hugel gave a presentation entitled Referral Pathway for Percutaneous Cordotomy. Action: Presentation to be circulated with notes All to share presentation and referral to cordotomy services with Palliative Care colleagues Heino to send annual referral activity figures/data within MCCN 5. CCO treatment data Discussed above under item Peer Review 2011/12 (including Clinical Lines of Enquiry CLOE and CNG work programme) Alison gave an update regarding evidence requirements. Alison will be circulating the following guidelines to the Trusts and they will also be available on website: Non small cell lung cancer oncology guidelines Small cell lung cancer guidelines MDT referral guidelines Lung CNG 3 key documents Alison is also awaiting confirmation of the following: Imaging guidelines Pathology reporting guidelines Follow up protocol Action: All to contact Alison if they require further MDT evidence 7 Clinical Trials recruitment and remedial action plans Lynne Newton informed the group that the research nurses are liaising more with clinicians and there has been progress in terms of recruitment into lung trials. Joe highlighted that reasons for poor uptake include a lack of availability of good trials to recruit to and a lack of congruence between the portfolio and what is routinely undertaken day to day. The majority of trials are only suitable for specialist groups. Alison referred to the inclusion of LHCH and CTC (same Trust) and also RLH being listed separately. These figures need to be amalgamated so that Trusts can appropriately consider their remedial action plans. Action: Lynne to feed back to MCCRN for action 8. Clinical Audit (CWT, LUCADA, CPI Report, PS Audit) Anna informed the group that MDT data in the CPI report has been validated for all Trusts. However, an issue has now been raised with the percentage of patients discussed at MDT, including those post Page 4 of 6 Page 4 of 6

5 mortem. Karen will look into the issue of recording of post mortem patients on SCR. The general consensus is that this is not required for the CPI report and the report can be signed off. With regards to the histology audit PS3/4 Anna has only received data from one Trust, the deadline is 1st October Action: Anna to present report on 2010 data at next Lung CNG The histology audit PS3/4 form to be re-circulated and move deadline to 1st November 2011; to be presented at next Lung CNG 9. NICE guidelines (summary) Paul Walker ed some comments from an Aintree perspective: Use of neck US where mediastinal lymph nodes are >20mm short axis on CT at present we would sample a neck node that is enlarged on CT but won t when not enlarged. There is an evidence base for wider use of neck US in stage III and IV disease but it isn t great and the recent Thorax paper adds nothing to what we already know. Our radiologists have raised this before and shown interest. Use of CT/MRI head where patient is undergoing curative surgery and has stage IIIA disease We don t perform this but have discussed this with respect to various patients at MDT. The other situation is where the primary tumour has a very high SUV on PET-CT our surgeon has commented that anecdotally these patients often come back with brain mets at an early stage. The point in the guidelines is consider but it may be worth us trying to get a position agreed. I do not know what the surgical practice is with respect to risk assessment for cardiovascular mortality before surgery and postponing patients for surgery to stop smoking but this should be clarified by the Network surgical leads to establish the current practice. It was felt generally that these weren t contentious or necessarily mandated issues. The general consensus amongst surgeons is that the Chest Physicians should get the staging data before the patient sees a Surgeon. Action: Richard Page to define high risk and agree criteria with view to trial this for 6 months and then do an audit to analyse the pick up rate across the network 10. Any Other Business Karen Graham circulated a letter on ACE-27 Co Morbidity Projects update on funding. NCIN have written to announce that this funding is now not available for 2011/2012 and as a result NCIN will not be able to support this project. However, Karen informed the meeting that the network is funding Tableaux which enables LUCADA data to be analysed. Tableaux license has gone out to all Trust Data Managers and is on the Desktops, all data managers have been trained and Anna is in the process of setting up the Desktops and getting a live feed from each service to the Desktops so that you can routinely review the LUCADA data. Action: Karen to keep the group updated CNS representative on Lung CNG if no one CNS can commit, representation can be on a rotational basis from the CNS group. Action: Kay to feedback to CNS group Page 5 of 6 Page 5 of 6

6 FOR INFORMATION 11. Lung CNG meetings 2012 Wednesday , 1.30 pm Wednesday , 1.30 pm Wednesday , 1.30 pm Wednesday pm All meetings will be held in the Network Meeting Room, Riverside Park Bromborough 12. Date of next meeting Monday 28 November 2011, 1.30 pm Network meeting room, Riverside Park, Bromborough CH62 3QX Page 6 of 6 Page 6 of 6

THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY

THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team Project Name: Peer Review Date: 26/05/2014 Release: FINAL Author: Owner: Client: Document Number: Timothy Jackson Cancer Information

More information

THYROID NSSG Wednesday 29 February 2012, 2:00pm Evolve Business Centre, Houghton-le-Spring

THYROID NSSG Wednesday 29 February 2012, 2:00pm Evolve Business Centre, Houghton-le-Spring THYROID NSSG Wednesday 29 February 2012, 2:00pm Evolve Business Centre, Houghton-le-Spring M I N U T E S Present: Kate Farnell, Patient Thyroid Cancer Advisor, Butterfly Trust KF Sarah Johnson, Consultant

More information

Lung Cancer Consultant Outcomes Publication

Lung Cancer Consultant Outcomes Publication Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

More information

The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients

The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients i Introduction The team of health professionals looking after you is known as the multidisciplinary

More information

The Characteristics of an Effective Multidisciplinary Team (MDT)

The Characteristics of an Effective Multidisciplinary Team (MDT) National Cancer Action Team The Characteristics of an Effective Multidisciplinary Team (MDT) February 2010 Contents Page Foreword The Characteristics of an Effective MDT Aim Introduction Categorisation

More information

Head and Neck MDT (UAT & UAT /Thyroid)

Head and Neck MDT (UAT & UAT /Thyroid) National Cancer Action Team National Cancer Peer Review Programme FOR: Head and Neck MDT (UAT & UAT /Thyroid) Introduction This evidence guide has been formulated to assist networks and their constituent

More information

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group Lung Cancer Multidisciplinary Meeting Toolkit National Lung Cancer Working Group September 2014 Contents Introduction 1 Multidisciplinary meetings 1 Toolkit for implementing high-quality lung cancer MDMs

More information

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010 Lung Cancer Network Group Lung Cancer Awareness Month November 2010 Lung cancer is the leading cause of cancer related death in the Northern Ireland and the UK 1,2. Each year in Northern Ireland approximately

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

GYNAECOLOGICAL ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY Version 3

GYNAECOLOGICAL ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY Version 3 GYNAECOLOGICAL ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY Version 3 Policy agreed Sept 2009 (updated Jan/Feb 2013) Agreed by: SCAN gynae group 2009 Update agreed SCAN gynae group May

More information

Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT)

Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) Oxford University Hospitals NHS Trust Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) This information leaflet explains the role of the Multi-Disciplinary Team and Specialist Nursing

More information

B10/S/a Cancer: Malignant Mesothelioma (Adult)

B10/S/a Cancer: Malignant Mesothelioma (Adult) B10/S/a 2013/14 NHS STANDARD CONTRACT FOR CANCER: MALIGNANT MESOTHELIOMA (ADULT) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No. Service Commissioner Lead Provider Lead Period Date

More information

Mesothelioma Priority Setting Partnership. PROTOCOL November 2013

Mesothelioma Priority Setting Partnership. PROTOCOL November 2013 Mesothelioma Priority Setting Partnership PROTOCOL November 2013 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Mesothelioma Priority Setting Partnership

More information

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals

More information

Guideline for the Follow Up of Patients Following Treatment for Breast Cancer

Guideline for the Follow Up of Patients Following Treatment for Breast Cancer Guideline for the Follow Up of Patients Following Treatment for Breast Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Page 1 of 6 1 Scope of the Guideline This guideline

More information

THYROID NSSG Wednesday 29 June 2011, 12:00pm The Board Room, Evolve Business Centre Video link with Carlisle

THYROID NSSG Wednesday 29 June 2011, 12:00pm The Board Room, Evolve Business Centre Video link with Carlisle THYROID NSSG Wednesday 29 June 2011, 12:00pm The Board Room, Evolve Business Centre Video link with Carlisle M I N U T E S Present: Nicola Armstrong, Thyroid Cancer Nurse Specialist, Newcastle Hospitals

More information

The Role of the MDT Coordinator. Laura Throssell

The Role of the MDT Coordinator. Laura Throssell The Role of the MDT Coordinator Laura Throssell NHS Cancer Plan (2000) the care of all patients with cancer should be formally reviewed by a specialist team. all patients have the benefit of the range

More information

Salisbury Lung Cancer Service (1 of 5)

Salisbury Lung Cancer Service (1 of 5) Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.

More information

2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)-

2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)- 2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)- SECTION B PART 1 - SERVICE SPECIFICATION FOR LUNG CANCER Service specification

More information

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers University College Hospital The lung cancer multidisciplinary team Information for patients and carers 2 If you would like this document in another language or format, or require the services of an interpreter,

More information

Wirral Specialist Palliative Care Service

Wirral Specialist Palliative Care Service Wirral Specialist Palliative Care Service Operational Policy 2012-13 Agreed date: 25 th September 2012 Review date: 25 th September 2013 Specialist Palliative Care Multi-disciplinary Team This Operational

More information

Information for Men Diagnosed with Testicular Cancer

Information for Men Diagnosed with Testicular Cancer Patient Information Service Information for Men Diagnosed with Testicular Cancer Bristol Haematology and Oncology Centre Bristol Testicular Cancer Service Patient Information is supported by September

More information

Patient Electronic Alert to Key-worker System (PEAKS) Guidelines

Patient Electronic Alert to Key-worker System (PEAKS) Guidelines Patient Electronic Alert to Key-worker System (PEAKS) Guidelines This procedural document supersedes: PAT/EC 4 v.1 Guidelines for Patient Electronic Alert to Key-worker systems (PEAKS). Did you print this

More information

Please see the LUCADA data manual v3.1.3, available in the downloads section

Please see the LUCADA data manual v3.1.3, available in the downloads section National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands

More information

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence.

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Leaders in Prostate Cancer Treatment and Research The Center for Prostate Cancer at the North

More information

Guidelines for Management of Renal Cancer

Guidelines for Management of Renal Cancer Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated

More information

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James

More information

Data Management, Audit and Outcomes

Data Management, Audit and Outcomes Data Management, Audit and Outcomes Providing Accurate Outcomes and Activity Data The Trust has in place robust mechanisms for capturing and reporting on all oesophago-gastric cancer surgery activity and

More information

National Lung Cancer Audit Report

National Lung Cancer Audit Report National Lung Cancer Audit Report 2013 Report for the audit period 2012 Copyright 2013, Health and Social Care Information Centre, National Lung Cancer Audit. All rights reserved. 1 Prepared in partnership

More information

State of the Nation: An overview of the impact and priorities for lung cancer in Northern Ireland

State of the Nation: An overview of the impact and priorities for lung cancer in Northern Ireland State of the Nation: An overview of the impact and priorities for lung cancer in Northern Ireland Introduction Lung cancer is Northern Ireland s biggest cancer killer. It causes more than one in five of

More information

The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes. UK Lung Cancer Coalition November 2012

The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes. UK Lung Cancer Coalition November 2012 The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes 1 UK Lung Cancer Coalition November 2012 November 2012 The Dream MDT for lung cancer Contents page Introduction 2 The

More information

Guide to Private Medical Insurance

Guide to Private Medical Insurance Guide to Private Medical Insurance Contents About the Exeter 4 Why private medical insurance? 5 Product highlights 6 Cover and benefits 10 Getting the right premium 15 How to apply 16 Claims overview 21

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years

This vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008

More information

NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY

NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY Statistics Commission Report No 2 May Statistics Commission Statistics Commission Report No. 2 National Statistics to

More information

How do I find the best place to get treatment for my lymphoma?

How do I find the best place to get treatment for my lymphoma? Produced November 2010 Next revision due November 2012 How do I find the best place to get treatment for my lymphoma? Introduction Fortunately this is not a question that patients with cancers of the blood

More information

Multidisciplinary Cancer Conferences (MCCs) Transforming the delivery of cancer care

Multidisciplinary Cancer Conferences (MCCs) Transforming the delivery of cancer care Multidisciplinary Cancer Conferences (MCCs) Transforming the delivery of cancer care Purpose To provide an introduction and background on MCCs To discuss how MCCs have been implemented across Ontario To

More information

What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide

What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide What If I Have a Spot on My Lung? Do I Have Cancer? Patient Education Guide A M E R I C A N C O L L E G E O F C H E S T P H Y S I C I A N S Lung cancer is one of the most common cancers. About 170,000

More information

Guide for families with children receiving Proton Beam Therapy abroad

Guide for families with children receiving Proton Beam Therapy abroad Xxxxxxxxxxxxxxxxxxxxx Guide for families with children receiving Proton Beam Therapy abroad Paediatric PBT Guide 2013 1 Contents Proton Beam Therapy explained (P4) What is radiotherapy? What is Proton

More information

The National Clinical Lung Cancer Audit (LUCADA)

The National Clinical Lung Cancer Audit (LUCADA) The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Breast. Patient information. cancer clinical pathway

Breast. Patient information. cancer clinical pathway Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather

More information

NEMICS Cancer Service Performance Indicator Audit Interim report 2014

NEMICS Cancer Service Performance Indicator Audit Interim report 2014 Cancer Service Performance Indicator Audit Interim report 2014 Date of report: January 5 th 2015 Sample period: May & Jun 2014 Origin of Indicators Cancer Strategy and Development Unit, Department of Health

More information

Activity Report March 2012 February 2013

Activity Report March 2012 February 2013 Upper Gastro-intestinal Cancer Managed Clinical Network Activity Report March 2012 February 2013 Mr Colin K MacKay Consultant Surgeon MCN Clinical Lead Margaret Welsh Network Service Manager CONTENTS EXECUTIVE

More information

National Framework for Excellence in

National Framework for Excellence in National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

Head and Neck Cancer Quality Performance Indicators

Head and Neck Cancer Quality Performance Indicators Information Services Division Publication Report Head and Neck Cancer Quality Performance Indicators Patients diagnosed during April 2014 to March 2015 Publication date 29 March 2016 An Official Statistics

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

Xxxxxxxxxxxxxxxxxxxxx. A guide for adult patients receiving Proton Beam Therapy abroad. Adult PBT Guide 2013 1

Xxxxxxxxxxxxxxxxxxxxx. A guide for adult patients receiving Proton Beam Therapy abroad. Adult PBT Guide 2013 1 Xxxxxxxxxxxxxxxxxxxxx A guide for adult patients receiving Proton Beam Therapy abroad Adult PBT Guide 2013 1 Contents Proton Beam Therapy explained (P4) What is Radiotherapy? What is Proton Beam Therapy?

More information

Manual for Cancer Services Breast Cancer Measures. Version 1.1

Manual for Cancer Services Breast Cancer Measures. Version 1.1 Manual for Cancer Services Breast Cancer Measures Version 1.1 VERSION CONTROL SHEET Date Version Changes Update by April 2013 1.1 Initial version Julia Hill Breast Cancer Measures GATEWAY No. 10790 - APRIL

More information

Minutes of Patient Participation Group (PPG) Meeting Beckett House Practice 7pm 8.30pm Wednesday 30 th July 2014

Minutes of Patient Participation Group (PPG) Meeting Beckett House Practice 7pm 8.30pm Wednesday 30 th July 2014 Minutes of Patient Participation Group (PPG) Meeting Beckett House Practice 7pm 8.30pm Wednesday 30 th July 2014 Attendance from the Practice: Dr Elizabeth McGinn (GP Partner), Sandra Connolly (Practice

More information

Cancer Services Operational Policy (Patient Access) Version number 2.1

Cancer Services Operational Policy (Patient Access) Version number 2.1 Cancer Services Operational Policy (Patient Access) V2.1 Cancer Services Operational Policy (Patient Access) Version number 2.1 Lead executive Name / title of author: Chief Operating Officer Karen Blackburn,

More information

PATIENT ACCESS POLICY

PATIENT ACCESS POLICY PATIENT ACCESS POLICY Document Type Policy Document Number Version Number 1.0 Approved by NHS Borders Board on 18 October 2012 Issue date Nov 2012 Review date Nov 2013 Distribution Prepared by Developed

More information

National Bowel Cancer Audit Report 2008 Public and Executive Summary

National Bowel Cancer Audit Report 2008 Public and Executive Summary National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland

More information

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850 LEBANON Lung Cancer Screening Program One Medical Center Drive Lebanon, NH 03756 (603) 650-4400 (866) 966-1601 Toll-free cancer.dartmouth.edu/lungscreening MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock

More information

PRESENT: Mr M Hill Modernisation Director (Chair) Mr J Anning Chair, North Lanarkshire CHP Mr P K Corsar Chair, NHS Board

PRESENT: Mr M Hill Modernisation Director (Chair) Mr J Anning Chair, North Lanarkshire CHP Mr P K Corsar Chair, NHS Board MINUTE OF THE SECOND MEETING OF THE PERFORMANCE MANAGEMENT GROUP HELD ON THURSDAY 25 JANUARY 2007 AT 9.00AM IN THE BOARD ROOM, NHS BOARD OFFICES, BECKFORD STREET, HAMILTON. PRESENT: Mr M Hill Modernisation

More information

Inflammatory breast cancer

Inflammatory breast cancer april 2007 information about Inflammatory breast cancer What is inflammatory breast cancer? Inflammatory breast cancer is a rare and rapidly growing form of breast cancer. Unlike other breast cancers which

More information

PATIENT ACCESS POLICY

PATIENT ACCESS POLICY . PATIENT ACCESS POLICY TITLE Patient Access Policy APPLICABLE TO All administrative / clerical / managerial staff involved in the administration of patient pathway. All medical and clinic staff seeing

More information

The Initial Chest X-ray at Certain Intervals in Patients with the First Presentation of Suspected Lung Cancer

The Initial Chest X-ray at Certain Intervals in Patients with the First Presentation of Suspected Lung Cancer Evidence Summary 25-1-2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Initial Chest X-ray at Certain Intervals in Patients with the First Presentation

More information

Mesothelioma in the UK

Mesothelioma in the UK Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma

More information

SOUTH AFRICAN PET USERS ASSOCIATION

SOUTH AFRICAN PET USERS ASSOCIATION SOUTH AFRICAN PET USERS ASSOCIATION Predicted demand for PET services in South Africa Introduction At the founding meeting of SAPUA held on the premises of Tygerberg Hospital on 4 December 2004 the newly

More information

Consent for Systemic Anti Cancer Therapy (SACT)

Consent for Systemic Anti Cancer Therapy (SACT) Consent for Systemic Anti Cancer Therapy (SACT) Guidance issued by the National Chemotherapy Board May 2016 Supported by: Contents National Chemotherapy Board 1. Introduction 1.1. Purpose of the guidance

More information

Statewide Respiratory Clinical Network

Statewide Respiratory Clinical Network Statewide Respiratory Clinical Network Steering Committee Terms of Reference May 2012 Table of Contents 1. Purpose... 3 2. Principal Functions... 3 3. Reporting Responsibilities... 4 4. Steering Committee...

More information

MINUTES 1. INTRODUCTION

MINUTES 1. INTRODUCTION Name of Group / Meeting: Network Service User Partnership Group Date: 20 May 2014 Time: 1:30 3:30 pm Venue: Evolve Business Centre Present: Tony Branson, Medical Director, NECN Sheila Brown, Sunderland

More information

How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion

How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How

More information

Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm

Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm NHSCB/A04/P/a NHS England: Guidance notes for commissioners

More information

Melanoma Quality Performance Indicators

Melanoma Quality Performance Indicators Publication Report Melanoma Quality Performance Indicators Patients diagnosed during July 2014 to June 2015 Publication date 17 May 2016 An Official Statistics Publication for Scotland Contents Introduction...

More information

Oncology and haematology clinical trials Information for patients at St Thomas Hospital

Oncology and haematology clinical trials Information for patients at St Thomas Hospital Oncology and haematology clinical trials Information for patients at St Thomas Hospital Contents p.2 Contents p.4 Welcome p.4 Meet the team p.6 Where will my appointment be? p.8 Tests and treatments and

More information

REPORT ON STOMA SERVICE AND PRACTICE. MM / YY to MM / YY. Name: Title: Centre:

REPORT ON STOMA SERVICE AND PRACTICE. MM / YY to MM / YY. Name: Title: Centre: REPORT ON STOMA SERVICE AND PRACTICE MM / YY to MM / YY Name: Title: Centre: 1 Contents 1.0 Introduction 2.0 Aims of the Stoma Care Service 3.0 Clinical Activity 4.0 Cost Saving Measures 5.0 Education

More information

National Cancer Rehabilitation Pathways. Rachel Atkinson AHP Lead May 2011

National Cancer Rehabilitation Pathways. Rachel Atkinson AHP Lead May 2011 National Cancer Rehabilitation Pathways Rachel Atkinson AHP Lead May 2011 National Cancer and Palliative Care Rehabilitation workforce Project One of the objectives was to produce 9 tumour specific, evidence

More information

Patient and Public Involvement and Engagement (PPI /E) Strategic Plan

Patient and Public Involvement and Engagement (PPI /E) Strategic Plan National Institute of Health Research (NIHR) Clinical Research Facility (CRF) in Imaging at The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London Patient and Public Involvement

More information

The Ontario Cancer Registry moves to the 21 st Century

The Ontario Cancer Registry moves to the 21 st Century The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer

More information

London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015

London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015 London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015 Sam Janes BSc MBBS FRCP MSc PhD Vice-Chair of the Lung Cancer CRG NHS England London Cancer Lung

More information

Treatment Routes in Prostate Cancer Urological Cancers SSCRG

Treatment Routes in Prostate Cancer Urological Cancers SSCRG 1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.

More information

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What? RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which

More information

Training in Clinical Radiology

Training in Clinical Radiology Training in Clinical Radiology What is Clinical Radiology? Clinical radiology relates to the diagnosis or treatment of a patient through the use of medical imaging. Diagnostic imaging uses plain X-ray

More information

Management of Non-Small Cell Lung Cancer Guide for General Practitioners

Management of Non-Small Cell Lung Cancer Guide for General Practitioners Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and

More information

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)

More information

Patient Participation Directed Enhanced Service 2012/13

Patient Participation Directed Enhanced Service 2012/13 Patient Participation Directed Enhanced Service 2012/13 Abbey View Medical Centre Report This report summarises the work that the Abbey View Patient Reference Group has undertaken during the last 12 months.

More information

PRIMARY LUNG CANCER TREATMENT

PRIMARY LUNG CANCER TREATMENT PRIMARY LUNG CANCER TREATMENT Cancer Care Pathways Directorate Tailored Information in Cancer Care (TICC) Sir Anthony Mamo Oncology Centre December 2014 Contents About this booklet 1 Types of Lung Cancer

More information

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board about progress on implementation of the Cancer Taskforce report.

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board about progress on implementation of the Cancer Taskforce report. Paper: PB.28.01.16/05 Title: Cancer Taskforce strategy implementation Lead Director: Bruce Keogh, National Medical Director Cally Palmer, National Cancer Director BOARD PAPER - NHS ENGLAND Purpose of Paper:

More information

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW

Surgery. Wedge resection only part of the lung, not. not a lobe, is removed. Cancer Council NSW The treatment you receive will depend on your lung cancer type, for example, whether you have a non-small cell lung cancer Adenocarcinoma or Squamous cell carcinoma, and if this is a sub-type with a mutation.

More information

Minutes of East Ayrshire Transition Integration Board 3pm, Wednesday 26 March 2014 Council Chambers, Council HQ, London Road, Kilmarnock

Minutes of East Ayrshire Transition Integration Board 3pm, Wednesday 26 March 2014 Council Chambers, Council HQ, London Road, Kilmarnock Minutes of East Ayrshire Transition Integration Board 3pm, Wednesday 26 March 2014 Council Chambers, Council HQ, London Road, Kilmarnock Present: In Attendance: Councillor Douglas Reid, EA Council, Chair

More information

INDIGENOUS CHRONIC DISEASE PACKAGE CARE COORDINATION AND SUPPLEMENTARY SERVICES PROGRAM GUIDELINES

INDIGENOUS CHRONIC DISEASE PACKAGE CARE COORDINATION AND SUPPLEMENTARY SERVICES PROGRAM GUIDELINES CLOSING THE GAP tackling disease INDIGENOUS CHRONIC DISEASE PACKAGE CARE COORDINATION AND SUPPLEMENTARY SERVICES PROGRAM GUIDELINES November 2012 CONTENTS 1. Introduction... 3 Program Context... 3 Service

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

PRESCRIBING OF NHS MEDICATION RECOMMENDED DURING OR AFTER A PRIVATE EPISODE OF CARE

PRESCRIBING OF NHS MEDICATION RECOMMENDED DURING OR AFTER A PRIVATE EPISODE OF CARE East Surrey CCG Guildford & Waverley CCG North West Surrey CCG Surrey Downs CCG Surrey Heath CCG PRESCRIBING OF NHS MEDICATION RECOMMENDED DURING OR AFTER A PRIVATE EPISODE OF CARE Version: 2.2 Name of

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners Follow-up care plan after treatment for breast cancer A guide for General Practitioners This leaflet provides information for GPs on the follow-up care required by women who had breast cancer. It is for

More information

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Saturday, April 27, 2013 Cleveland Marriott Downtown at Key Center 127 Public Square Cleveland, Ohio Learning

More information

Low-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital

Low-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the

More information

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10 Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the

More information